LIQUIDIA_Logo.jpg
Liquidia Technologies Reports Positive Interim LIQ861 Safety Data on 109 Patients from Pivotal INSPIRE Trial
January 07, 2019 07:00 ET | Liquidia Technologies, Inc.
LIQ861 was well-tolerated in PAH patients at two-weeks of treatment, the safety endpoint requested by U.S. FDANDA submission targeted for late 2019 RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2019 ...
LIQUIDIA_Logo.jpg
Liquidia Technologies Provides Leadership Update
November 27, 2018 16:45 ET | Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and...
LIQUIDIA_Logo.jpg
Liquidia Technologies Recipient of Best-in-Class Public Offering Award at Southeast BIO
November 14, 2018 16:30 ET | Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and...
LIQUIDIA_Logo.jpg
Liquidia Technologies to Present LIQ865 Phase 1a Data at ASRA’s 17th Annual Pain Medicine Meeting
November 14, 2018 08:00 ET | Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and...
LIQUIDIA_Logo.jpg
Liquidia Technologies to Present at Jefferies London Healthcare Conference
November 09, 2018 08:00 ET | Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and...
LIQUIDIA_Logo.jpg
Liquidia Technologies Reports Third Quarter 2018 Financial Results and Provides Corporate Update
October 31, 2018 07:00 ET | Liquidia Technologies, Inc.
Completed enrollment of the safety portion of our Ph3 LIQ861 (INSPIRE) clinical trialTwo-week safety Ph3 LIQ861 data readout anticipated in the first quarter of 2019Dr. Stephen Bloch appointed as...
LIQUIDIA_Logo.jpg
Liquidia Technologies to Provide Third Quarter 2018 Corporate Update on October 31, 2018
October 23, 2018 08:00 ET | Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development...
LIQUIDIA_Logo.jpg
Liquidia Technologies Added to Russell 2000®, 3000® and Microcap® Indexes
September 24, 2018 08:00 ET | Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development...
Liquidia Technologies to Present at Wedbush PacGrow Healthcare Conference
August 09, 2018 08:00 ET | Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and...